在存在病毒蛋白酶抑制剂的情况下，人类免疫缺陷病毒1型复制早期步骤的进展
Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease.
作者信息
Jacobsen H, Ahlborn-Laake L, Gugel R, Mous J
机构信息
Department PRTB, F. Hoffmann-LaRoche, Basel, Switzerland.
出版信息
J Virol. 1992 Aug;66(8):5087-91. doi: 10.1128/JVI.66.8.5087-5091.1992.
Abstract
We have evaluated a possible role for human immunodeficiency virus type 1 protease during early steps of replication. For these studies, a specific inhibitor of human immunodeficiency virus protease, Ro31-8959, was used. Synthesis of viral cDNA, its integration into cellular DNA, and its transcription were determined during a one-step, acute infection of MT-4 cells. No consistent difference in any of these parameters was noted between control-infected cultures and those treated with protease inhibitor. However, no infectious progeny virus was produced in treated cultures, and thus spread of infection was severely restricted. Our results do not support an essential activity of viral protease in early steps of replication but are in line with its established role in gag and gag-pol processing and in maturation to infectious progeny virus.
摘要
我们评估了1型人类免疫缺陷病毒蛋白酶在复制早期阶段可能发挥的作用。在这些研究中，使用了一种人类免疫缺陷病毒蛋白酶的特异性抑制剂Ro31-8959。在MT-4细胞的一步急性感染过程中，测定了病毒cDNA的合成、其整合到细胞DNA中的情况及其转录。在对照感染的培养物和用蛋白酶抑制剂处理的培养物之间，未观察到这些参数中的任何一致差异。然而，在用抑制剂处理的培养物中未产生有感染性的子代病毒，因此感染的传播受到严重限制。我们的结果不支持病毒蛋白酶在复制早期阶段具有必需活性，但与其在gag和gag-pol加工以及成熟为有感染性子代病毒方面已确立的作用一致。
相似文献
1
Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease.
J Virol. 1992 Aug;66(8):5087-91. doi: 10.1128/JVI.66.8.5087-5091.1992.
2
HIV-1 proteinase is required for synthesis of pro-viral DNA.
Biochem Biophys Res Commun. 1991 Aug 30;179(1):17-24. doi: 10.1016/0006-291x(91)91327-9.
3
Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.
J Virol. 1994 Feb;68(2):757-65. doi: 10.1128/JVI.68.2.757-765.1994.
4
De novo reverse transcription is a crucial event in cell-to-cell transmission of human immunodeficiency virus.
J Gen Virol. 1992 Apr;73 ( Pt 4):955-9. doi: 10.1099/0022-1317-73-4-955.
5
Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro.
J Med Virol. 1999 Jun;58(2):165-73. doi: 10.1002/(sici)1096-9071(199906)58:2<165::aid-jmv11>3.0.co;2-1.
6
Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication.
J Virol. 1996 Apr;70(4):2146-53. doi: 10.1128/JVI.70.4.2146-2153.1996.
7
Human immunodeficiency virus type 1 infection requires reverse transcription of nascent viral RNA.
DNA Cell Biol. 1993 Oct;12(8):685-93. doi: 10.1089/dna.1993.12.685.
8
Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication.
J Virol. 1995 Feb;69(2):814-24. doi: 10.1128/JVI.69.2.814-824.1995.
9
Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection.
Antiviral Res. 1993 Aug;21(4):327-42. doi: 10.1016/0166-3542(93)90011-7.
10
An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection.
Proc Natl Acad Sci U S A. 1990 Oct;87(19):7472-6. doi: 10.1073/pnas.87.19.7472.
引用本文的文献
1
Cellular Targets of HIV-1 Protease: Just the Tip of the Iceberg?
Viruses. 2023 Mar 9;15(3):712. doi: 10.3390/v15030712.
2
Specificity of the HIV-1 Protease on Substrates Representing the Cleavage Site in the Proximal Zinc-Finger of HIV-1 Nucleocapsid Protein.
Viruses. 2021 Jun 8;13(6):1092. doi: 10.3390/v13061092.
3
Effect of internal cleavage site mutations in human immunodeficiency virus type 1 capsid protein on its structure and function.
FEBS Open Bio. 2016 Jun 30;6(8):847-59. doi: 10.1002/2211-5463.12094. eCollection 2016 Aug.
4
HIV-1 protease cleaves eukaryotic initiation factor 4G and inhibits cap-dependent translation.
Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):12966-71. doi: 10.1073/pnas.231343498. Epub 2001 Oct 23.
5
Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture.
Antimicrob Agents Chemother. 1999 Nov;43(11):2629-34. doi: 10.1128/AAC.43.11.2629.
6
Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection.
Drugs. 1996 Jul;52(1):93-112. doi: 10.2165/00003495-199652010-00007.
7
Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication.
J Virol. 1996 Sep;70(9):5840-4. doi: 10.1128/JVI.70.9.5840-5844.1996.
8
Anti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase.
Antimicrob Agents Chemother. 1995 Sep;39(9):2000-7. doi: 10.1128/AAC.39.9.2000.
9
Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.
J Virol. 1993 Jul;67(7):4050-5. doi: 10.1128/JVI.67.7.4050-4055.1993.
10
Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.
J Virol. 1994 Feb;68(2):757-65. doi: 10.1128/JVI.68.2.757-765.1994.
本文引用的文献
1
Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.
Proc Natl Acad Sci U S A. 1980 Sep;77(9):5201-5. doi: 10.1073/pnas.77.9.5201.
2
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature. 1970 Aug 15;227(5259):680-5. doi: 10.1038/227680a0.
3
Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor.
Proc Natl Acad Sci U S A. 1987 Dec;84(24):8903-6. doi: 10.1073/pnas.84.24.8903.
4
Active human immunodeficiency virus protease is required for viral infectivity.
Proc Natl Acad Sci U S A. 1988 Jul;85(13):4686-90. doi: 10.1073/pnas.85.13.4686.
5
Viral proteinases.
Annu Rev Biochem. 1988;57:701-54. doi: 10.1146/annurev.bi.57.070188.003413.
6
Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A.
Proc Natl Acad Sci U S A. 1988 Sep;85(18):6612-6. doi: 10.1073/pnas.85.18.6612.
7
Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.
Science. 1985 Aug 9;229(4713):563-6. doi: 10.1126/science.2992081.
8
Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression.
J Virol. 1989 Sep;63(9):3708-13. doi: 10.1128/JVI.63.9.3708-3713.1989.
9
Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides.
Proc Natl Acad Sci U S A. 1989 Feb;86(3):807-11. doi: 10.1073/pnas.86.3.807.
10
Mutational analysis of human immunodeficiency virus type 1 protease suggests functional homology with aspartic proteinases.
J Virol. 1989 Jan;63(1):111-21. doi: 10.1128/JVI.63.1.111-121.1989.
Zotero 插件